Menu

The Economic Stimulus and Science

A fixed percentage of a country's GDP should be committed to research.

Mar 1, 2009
Alastair J.J. Wood
Credit: © Brian Stauffer

In early February, the House voted to approve the $787 billion economic recovery package and this was signed into law by President Obama. The bill contains something for everyone including scientists—$10 billion for National Institutes of Health (NIH), $1.3 billion for the National Center for Research Resources (NCRR), including $1 billion for construction and renovation of extramural research facilities, $700 million for the Agency for Healthcare Research and Quality (AHRQ) and $2.5 billion for the National Science Foundation (NSF).

Were it not that the purpose of the bill was to attempt a rescue of our teetering economy, this would indeed be a time to celebrate. The additional funds to the scientific enterprise is sorely needed and long overdue but it is hard not to have some misgivings at the manifest "short termism" of the overall scientific funding process. For example, language included in the bill instructs the NIH director that $800 million of the additional funding "shall be used for purposes that can be completed in two years." The time has come to fundamentally reexamine the process of funding scientific research in The United States.

Scientific research is a never-ending process of painstaking work and long-term commitment; few projects of true scientific merit can be started and finished in two years.

The return on investment in scientific research has been staggering both in terms of economic progress and in the improvement in health and quality of life. Yet research is funded as though it was "white-coat welfare", with money doled out episodically and unreliably.

The disconnect between our science-based future and bricks-and-mortar past was never clearer than in the discussion of the economic stimulus package where states vied for funding by convincing Congress that their projects were "shovel ready". The country's future lies in high-technology and science, not just in wielding shovels. Funding must encourage our brightest young people to enter careers in science and to obtain the qualifications and training to do so by demonstrating the nation's long term and sustained commitment to the scientific endeavor. Demonstration of the nation's long term commitment will require protecting the budget for scientific research from the vagaries of the annual congressional budget negotiations.

The current system of funding results in boom and bust cycles that sap confidence and continuity. The doubling of the NIH budget from 1998-2003 increased the number of funded grants but these came up for renewal when the budget was not keeping up with inflation, resulting in loss of jobs, confidence and commitment. The average age of R01 funded investigators is now over 50, while the average age of first time R01 awardees is almost 43, and even higher for MD investigators. This is unsustainable. What intelligent young person will commit to a career in which the first measure of independent funding does not occur until their mid-forties?

We need a radical change to the way we fund scientific research. A fixed percentage of the nation's GDP should be committed to research funding. Such a predictable commitment will demonstrate the recognition that our future rests in scientific advances. Such a reliable commitment will ensure that well qualified individuals will see a future for themselves and their families in joining the research endeavor. Such a dependable commitment will allow universities to rationally plan their investments in research infrastructure and will restore our international scientific competitive position, which is being lost to countries who have adopted such commitments.

Alastair J.J. Wood is a managing director at the biopharmaceutical investment firm of Symphony Captial and a member of The Scientist's Editorial Advisory Board.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.